Cargando…

Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation

Acute myeloid leukemia (AML) is a heterogeneous disease often associated with poor prognosis. We previously showed that the localization of KIT-D816V at endolysosomes is critical to activate aberrant Akt signaling and Chlorpromazine (CPZ) perturbs the intracellular localization, leading to cell deat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rai, Shinya, Tanaka, Hirokazu, Espinoza, J. Luis, Kumode, Takahiro, Matsumura, Itaru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233227/ https://www.ncbi.nlm.nih.gov/pubmed/34194969 http://dx.doi.org/10.1016/j.lrr.2021.100256

Ejemplares similares

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V
por: Rai, Shinya, et al.
Publicado: (2020)

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
por: Kumode, Takahiro, et al.
Publicado: (2020)

The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia
por: Taniguchi, Yasuhiro, et al.
Publicado: (2020)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
por: Sandow, Lyndsey, et al.
Publicado: (2023)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia
por: Lopes, Marta, et al.
Publicado: (2018)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
por: Rai, Shinya, et al.
Publicado: (2018)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia
por: Miyatake, Junichi, et al.
Publicado: (2018)

De novo Leukemic Variant of Mast Cell Leukemia With KIT D816V
por: Bang, Hae In, et al.
Publicado: (2015)

Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation
por: Suh, Myung Chul, et al.
Publicado: (2017)

Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality
por: Rai, Shinya, et al.
Publicado: (2019)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material
por: Kähler, Christian, et al.
Publicado: (2007)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
por: Wang, Biao, et al.
Publicado: (2020)

Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy
por: Inoue, Hiroaki, et al.
Publicado: (2020)

Discovery of novel heteroaryl alkynes for highly potent KIT(D816V) cells inhibition to treat gastrointestinal stromal tumors
por: Xie, Zhicheng, et al.
Publicado: (2022)

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
por: Cho, Byung-Sik, et al.
Publicado: (2021)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2022)

Detection of KIT mutations in core binding factor acute myeloid leukemia
por: Badr, Passant, et al.
Publicado: (2018)

ECT-CHLORPROMAZINE COMBINATION COMPARED WITH CHLORPROMAZINE ONLY IN SCHIZOPHRENIA1
por: Janakiramaiah, N., et al.
Publicado: (1981)

Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma
por: Rai, Shinya, et al.
Publicado: (2021)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
por: Grootens, Jennine, et al.
Publicado: (2019)

Clathrin Assembly Protein CALM Plays a Critical Role in KIT Signaling by Regulating Its Cellular Transport from Early to Late Endosomes in Hematopoietic Cells
por: Rai, Shinya, et al.
Publicado: (2014)

Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells
por: Tanaka, Hirokazu, et al.
Publicado: (2019)

A Peptide Vaccine Design Targeting KIT Mutations in Acute Myeloid Leukemia
por: Kim, Minji, et al.
Publicado: (2023)

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
por: Kampa-Schittenhelm, Kerstin M., et al.
Publicado: (2018)

Congenital Acute Myeloid Leukemia with t(8;16) and t(17;19) Double Translocation: Case Presentation and Literature Review
por: Sung, Tae-Jung, et al.
Publicado: (2010)

PB1815: T(8;16)(P11;P13): A RARE CASE OF ACUTE MYELOID LEUKEMIA
por: Cuccurullo, R., et al.
Publicado: (2022)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

Mutation D816V Alters the Internal Structure and Dynamics of c-KIT Receptor Cytoplasmic Region: Implications for Dimerization and Activation Mechanisms
por: Laine, Elodie, et al.
Publicado: (2011)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
por: Tobío, Araceli, et al.
Publicado: (2020)

Chlorpromazine-induced lenticular opacity
por: Srinivasan, Kavitha, et al.
Publicado: (2020)

Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation
por: Möller Westerberg, C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0kggu7mdtsl54d4vrn5u9tktim